Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.54 |
| ▸ | HSPA1A | P0DMV8 | 1/20 | 0.52 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.52 |
| ▸ | HSPA9 | P38646 | 1/20 | 0.52 |
| ▸ | HSPA2 | P54652 | 1/20 | 0.52 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | HPGDS | O60760 | 2/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17994240 | 0.92 | CTSL (0.53) | CTSLHSPA1AHSPA5HSPA9HSPA2 | |
| SCHEMBL16375201 | 0.90 | CTSL (0.53) | CTSLHSPA1AHSPA5HSPA9HSPA2 | |
| SCHEMBL16375232 | 0.88 | L3MBTL1 (0.59) | CTSLMMEL1L3MBTL1CTSBCTSS | |
| SCHEMBL16375213 | 0.86 | HSPA1A (0.53) | CTSLHSPA1AHSPA5HSPA9HSPA2 | |
| SCHEMBL16375208 | 0.84 | HSPA5 (0.51) | CTSLHSPA1AHSPA5HSPA9HSPA2 | |
| SCHEMBL16375203 | 0.84 | CTSL (0.53) | CTSLHSPA1AHSPA5HSPA9HSPA2 | |
| SCHEMBL16306220 | 0.81 | GCGR (0.56) | CTSLMMEL1L3MBTL1CTSBCTSS | |
| SCHEMBL17994241 | 0.81 | L3MBTL1 (0.57) | CTSLMMEL1L3MBTL1CTSBCTSS | |
| SCHEMBL16305697 | 0.78 | GCGR (0.53) | CTSLMMEL1L3MBTL1CTSBCTSS | |
| SCHEMBL16294330 | 0.78 | GCGR (0.53) | CTSLMMEL1L3MBTL1CTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170313717-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2017-11-02 | — | — | US | disclosed |
| US-9598430-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-03-21 | — | — | US | disclosed |
| US-20160214993-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-07-28 | — | — | US | disclosed |
| US-20150011527-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313717-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | CTSL 1635/4885HSPA1A 2012/4885HSPA5 3669/4885 |
| US-20160214993-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | CTSL 1635/4885HSPA1A 2012/4885HSPA5 3669/4885 |
| US-20150011527-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | CTSL 1635/4885HSPA1A 2012/4885HSPA5 3669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.